<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477096</url>
  </required_header>
  <id_info>
    <org_study_id>HS-10234-108</org_study_id>
    <nct_id>NCT04477096</nct_id>
  </id_info>
  <brief_title>Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine</brief_title>
  <official_title>Study on the Drug Interaction of HS-10234 and Emtricitabine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine
      after multiple dose in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234.
      Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine</measure>
    <time_frame>0 - 24 hour on 7th day</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine</measure>
    <time_frame>0 - 24 hour on 7th day</time_frame>
    <description>AUC0-tau</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells.</measure>
    <time_frame>0 - 24 hour on 7th day</time_frame>
    <description>Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>laboratory abnormalities (based on hematology, biochemistry, and urinalysis tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>respiratory rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs,</measure>
    <time_frame>0 - 23 day</time_frame>
    <description>Resting 12-lead ECG parameters（ECG QT Interval）</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>single arm for each part: two arms</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.
PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-10234</intervention_name>
    <description>HS-10234</description>
    <arm_group_label>single arm for each part: two arms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>Emtricitabine</description>
    <arm_group_label>single arm for each part: two arms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntarily sign an informed consent before any activities related to this trial and
             understand the procedures and methods of this trial;

          2. Aged between 18 and 55 years old (including cutoff value), both male and female;

          3. Male body weight ≥50.0kg, female body weight ≥45.0kg, body mass index (BMI) is 19~26
             kg/m2 (including both ends);

          4. Those who signed the informed consent form and had no birth plan within 3 months after
             the last dose and agreed to take effective contraceptive measures.

        Exclusion Criteria:

          1. People who have been or are currently suffering from any clinically serious diseases
             such as circulatory system, endocrine system, nervous system, digestive system,
             respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or
             any other diseases that can interfere with the test results, Or have a stomach problem
             or have a history of stomach problems;

          2. People who have drugs (penicillin or cephalosporin drugs), food, or have a history of
             allergy to test drugs or similar drugs;

          3. If the subject have a history of surgery within the 4 weeks prior to the trial or plan
             to undergo surgery during the study period or have surgery that affected the
             absorption, distribution, metabolism, and excretion of drugs;

          4. Those who took any prescription drugs, over-the-counter drugs, Chinese herbal
             medicines or health products within 14 days before taking the study drug, or those who
             were within 5 half-lives of the drug at the time of screening; those who plan to take
             non-study drugs or health products during the trial;

          5. Those who participated in any drug clinical trial and used any trial drug within 3
             months before administration (subject to the informed consent);

          6. Participate in blood donation within 3 months before administration and the amount of
             blood donation &gt;200 mL, or have received blood transfusion;

          7. Unable or unwilling to follow the lifestyle guidelines required in the plan;

          8. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the
             trial;

          9. Alcoholics or frequent drinkers within 6 months before the test, that is, drinking
             more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40%
             alcohol or 150 mL of wine) or before administration Alcohol screening positive;

         10. People who have a history of drug abuse, drug dependence, or a positive drug screen
             before administration;

         11. Screening/baseline visit to alanine aminotransferase and/or aspartate aminotransferase
             and/or alkaline phosphatase and/or total bilirubin exceeds 1.2 times the upper limit
             of normal;

         12. Abnormal vital signs (systolic blood pressure &lt;90 mmHg or &gt;140 mmHg, diastolic blood
             pressure &lt;50 mmHg or &gt;90 mmHg; pulse &lt;50 bpm or &gt;100 bpm) or physical examination,
             electrocardiogram, laboratory examination, imaging examination, etc. Abnormality has
             clinical significance (subject to the judgment of the clinical research doctor);

         13. The QT interval is prolonged during screening (calculated using Bazett's method,
             male&gt;450 msec, female&gt;460 msec);

         14. Hepatitis B surface antigen, hepatitis C antibody, syphilis serotonin, HIV antibody
             test positive;

         15. Women during pregnancy or lactation;

         16. Subjects may not be able to complete the study for other reasons or the investigator
             believes that they should not be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Huang</last_name>
    <phone>86-151 1646 9024</phone>
    <email>cellahuang1988@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guoping Yang, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 19, 2020</last_update_submitted>
  <last_update_submitted_qc>July 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

